Nibbling at CRF receptor control of feeding and gastrocolonic motility

Trends in Pharmacological Sciences

Volumn 24, Issue 8, 2003, Pages 421-427

  Zorrilla, Eric P ^a   Taché, Yvette ^b   Koob, George F ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [N (2 BROMO 4 ISOPROPYLPHENYL) N ETHYLAMINO] 4 [4 (3 FLUOROPHENYL) 1,2,3,6 TETRAHYDRO 1 PYRIDINYL] 6 METHYLPYRIMIDINE; 3 (6 DIMETHYLAMINO 4 METHYL 3 PYRIDINYL) 7 DIPROPYLAMINO 2,5 DIMETHYLPYRAZOLO[1,5 A]PYRIMIDINE; 3 [6 (DIMETHYLAMINO) 3 PYRIDINYL] 2,5 DIMETHYL N,N DIPROPYLPYRAZOLO[1,5 A]PYRIMIDIN 7 AMINE; 4 (2 CHLORO 4 METHOXY 5 METHYLPHENYL) N [2 CYCLOPROPYL 1 (3 FLUORO 4 METHYLPHENYL)ETHYL] 5 METHYL N (2 PROPYNYL) 2 THIAZOLAMINE; 4 (2 CHLORO 4 METHOXY 5 METHYLPHENYL) N [2 CYCLOPROPYL 1 (3 FLUORO 4 METHYLPHENYL)ETHYL] 5 METHYL N (2 PROPYNYL)THIAZOL 2 AMINE; 4 [4 (3 FLUOROPHENYL) 1,2,3,6 TETRAHYDRO 1 PYRIDINYL] 2 [N ETHYL N (4 ISOPROPYL 2 METHYLTHIOPHENYL)AMINO] 6 METHYLPYRIMIDINE; 5 CHLORO 4 [N (CYCLOPROPYLMETHYL) N PROPYLAMINO] 2 METHYL 6 (2,4,6 TRICHLOROANILINO)PYRIMIDINE; 8 (2,4 DICHLOROPHENYL) 4 [2 METHOXY 1 (METHOXYMETHYL)ETHYLAMINO] 2,7 DIMETHYLPYRAZOLO[1,5 A][1,3,5]TRIAZINE; ANTALARMIN; ASTRESSIN; BUTYL[2,5 DIMETHYL 7 (2,4,6 TRIMETHYLPHENYL) 7H PYRROLO[2,3 D]PYRIMIDIN 4 YL]ETHYLAMINE; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; CORTICOTROPIN RELEASING FACTOR RECEPTOR; CORTICOTROPIN RELEASING FACTOR RECEPTOR AGONIST; DMP 695; DMP 904; HORMONE RECEPTOR STIMULATING AGENT; K 31440; K 41498; N (1 ETHYLPROPYL) 3 (4 METHOXY 2 METHYLPHENYL) 2,5 DIMETHYLPYRAZOLO[1,5 A]PYRIMIDIN 7 AMINE; N (2 CHLORO 4,6 DIMETHYLPHENYL) 1 [1 METHOXYMETHYL (2 METHOXYETHYL)] 6 METHYL 1H 1,2,3 TRIAZOLO[4,5 C]PYRIDIN 4 AMINE MESYLATE; N (2 METHYL 4 METHOXYPHENYL) 1 [1 (METHOXYMETHYL)PROPYL] 6 METHYL 1H 1,2,3 TRIAZOLO[4,5 C]PYRIDIN 4 AMINE; PEPTIDE DERIVATIVE; SAUVAGINE; SN 003; UNCLASSIFIED DRUG; UROCORTIN;

ANIMAL BEHAVIOR; ANOREXIA; ANXIETY DISORDER; CHOLINERGIC SYSTEM; DRUG EFFECT; DRUG RECEPTOR BINDING; FEEDING; FOOD INTAKE; GASTROINTESTINAL MOTILITY; MALAISE; MYENTERIC PLEXUS; NONHUMAN; PRIORITY JOURNAL; REVIEW; SATIETY; STRESS;

EID: 0042661175     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-6147(03)00177-9     Document Type: Review

References (60)

1. Vale W., et al. Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin. Science. 213:1981;1394-1397.
2. Richard D., et al. The corticotropin-releasing factor family of peptides and CRF receptors: their roles in the regulation of energy balance. Eur. J. Pharmacol. 440:2002;189-197.
3. Dautzenberg F.M., Hauger R.L. The CRF peptide family and their receptors: yet more partners discovered. Trends Pharmacol. Sci. 23:2002;71-77.
4. Hauger R.L., et al. International Union of Pharmacology. XXXVI. current status of the nomenclature for receptors for corticotropin-releasing factor and their ligands. Pharmacol. Rev. 55:2003;21-26.
5. Vaughan J., et al. Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotropin-releasing factor. Nature. 378:1995;287-292.
6. Coste S.C., et al. Abnormal adaptations to stress and impaired cardiovascular function in mice lacking corticotropin-releasing hormone receptor-2. Nat. Genet. 24:2000;403-409.
7. Pelleymounter M.A., et al. Role of corticotropin-releasing factor (CRF) receptors in the anorexic syndrome induced by CRF. J. Pharmacol. Exp. Ther. 293:2000;799-806.
8. Smagin G.N., et al. The role of CRF2 receptors in corticotropin-releasing factor- and urocortin-induced anorexia. NeuroReport. 9:1998;1601-1606.
9. Reyes T.M., et al. Urocortin II: a member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by type 2 CRF receptors. Proc. Natl. Acad. Sci. U. S. A. 98:2001;2843-2848.
10. Lewis K., et al. Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor. Proc. Natl. Acad. Sci. U. S. A. 98:2001;7570-7575.
11. Hsu S.Y., Hsueh A.J. Human stresscopin and stresscopin-related peptide are selective ligands for the type 2 corticotropin-releasing hormone receptor. Nat. Med. 7:2001;605-611.
12. Li C., et al. Urocortin III-immunoreactive projections in rat brain: partial overlap with sites of type 2 corticotrophin-releasing factor receptor expression. J. Neurosci. 22:2002;991-1001.
13. Bittencourt J.C., et al. Urocortin expression in rat brain: evidence against a pervasive relationship of urocortin-containing projections with targets bearing type 2 CRF receptors. J. Comp. Neurol. 415:1999;285-312.
14. Kozicz T., Arimura A. Distribution of urocortin in the rat's gastrointestinal tract and its colocalization with tyrosine hydroxylase. Peptides. 23:2002;515-521.
15. 123I-K31440 as a potential SPECT ligand. Peptides. 23:2002;453-460.
16. 2 receptors in rat brain. Br. J. Pharmacol. 136:2002;896-904.
17. Brauns O., et al. Secondary structure of antisauvagine analogues is important for CRF receptor antagonism: development of antagonists with increased potency and receptor selectivity. Peptides. 23:2002;1817-1827.
18. Rivier J., et al. Potent and long acting corticotropin releasing factor (CRF) receptor 2 selective peptide competitive antagonists. J. Med. Chem. 45:2002;4737-4747.
19. Sánchez M.M., et al. Autoradiographic and in situ hybridization localization of corticotropin-releasing factor 1 and 2 receptors in nonhuman primate brain. J. Comp. Neurol. 408:1999;365-377.
20. Seymour P.A., et al. The pharmacology of CP-154,526, a non-peptide antagonist of the CRH1 receptor: a review. CNS Drug Rev. 9:2003;57-96.
21. Wang L., et al. Peripheral urocortin inhibits gastric emptying and food intake in mice: differential role of CRF receptor 2. Am. J. Physiol. Regul. Integr. Comp. Physiol. 281:2001;R1401-R1410.
22. Weisinger R.S., et al. The inhibitory effect of hormones associated with stress on Na appetite of sheep. Proc. Natl. Acad. Sci. U. S. A. 97:2000;2922-2927.
23. Inoue K., et al. Human urocortin II, a selective agonist for the type 2 corticotropin-releasing factor receptor, decreases feeding and drinking in the rat. J. Pharmacol. Exp. Ther. 305:2003;385-393.
24. Valdez G.R., et al. Human urocortin II: mild locomotor suppressive and delayed anxiolytic-like effects of a novel corticotropin-releasing factor related peptide. Brain Res. 943:2002;142-150.
25. Valdez, G.R. et al. Locomotor suppressive and anxiolytic-like effects of urocortin III, a highly selective type 2 corticotropin-releasing factor agonist. Brain Res. (in press).
26. Hotta M., et al. Corticotropin-releasing factor receptor type 1 mediates emotional stress-induced inhibition of food intake and behavioral changes in rats. Brain Res. 823:1999;221-225.
27. Taché Y., et al. Stress and the gastrointestinal tract III. Stress-related alterations of gut motor function: role of brain corticotropin-releasing factor receptors. Am. J. Physiol. Gastrointest. Liver Physiol. 280:2001;G173-G177.
28. 2-mediated action on gastric transit in rats. Am. J. Physiol. Gastrointest. Liver Physiol. 282:2002;G34-G40.
29. Kihara N., et al. Effects of central and peripheral urocortin on fed and fasted gastroduodenal motor activity in conscious rats. Am. J. Physiol. Gastrointest. Liver Physiol. 280:2001;G406-G419.
30. Chen C.Y., et al. Intracisternal urocortin inhibits vagally stimulated gastric motility in rats: role of CRF(2). Br. J. Pharmacol. 136:2002;237-247.
31. McCarthy J.R., et al. Recent advances with the CRF1 receptor: design of small molecule inhibitors, receptor subtypes and clinical indications. Curr. Pharm. Des. 5:1999;289-315.
32. Martinez V., et al. Differential actions of peripheral corticotropin-releasing factor (CRF), urocortin II, and urocortin III on gastric emptying and colonic transit in mice: role of CRF receptor subtypes 1 and 2. J. Pharmacol. Exp. Ther. 301:2002;611-617.
33. Gilligan P.J., et al. The discovery of 4-(3-pentylamino)-2,7-dimethyl-8-(2-methyl-4-methoxyphenyl)-pyrazolo- [1,5-a]-pyrimidine: a corticotropin-releasing factor (hCRF1) antagonist. Bioorg. Med. Chem. 8:2000;181-189.
34. Wang L., et al. Fos induction in selective hypothalamic neuroendocrine and medullary nuclei by intravenous injection of urocortin and corticotropin-releasing factor in rats. Brain Res. 855:2000;47-57.
35. Taché Y., et al. Role of corticotropin-releasing factor receptor subtype 1 in stress-related functional colonic alterations: implications in irritable bowel syndrome. Eur. J. Surg. Suppl. 587:2002;168-170.
36. Maillot C., et al. Peripheral corticotropin-releasing factor and stress-stimulated colonic motor activity involve type 1 receptor in rats. Gastroenterology. 119:2000;1569-1579.
37. Martinez V., Taché Y. Role of CRF receptor 1 in central CRF-induced stimulation of colonic propulsion in rats. Brain Res. 893:2001;29-35.
38. 1 receptor in conscious rats. Am. J. Physiol. Gastrointest. Liver Physiol. 282:2002;G857-G865.
39. 2 receptors in behavioral, but not endocrine, response to environmental stress. J. Pharmacol. Exp. Ther. 302:2002;145-152.
40. Muglia L.J., et al. The physiology of corticotropin-releasing hormone deficiency in mice. Peptides. 22:2001;725-731.
41. Vetter D.E., et al. Urocortin-deficient mice show hearing impairment and increased anxiety-like behavior. Nat. Genet. 31:2002;363-369.
42. Wang X., et al. Urocortin-deficient mice display normal stress-induced anxiety behavior and autonomic control but an impaired acoustic startle response. Mol. Cell. Biol. 22:2002;6605-6610.
43. Arai M., et al. Characterization of three corticotropin-releasing factor receptors in catfish: a novel third receptor is predominantly expressed in pituitary and urophysis. Endocrinology. 142:2001;446-454.
44. Nishiyama M., et al. Leptin effects on the expression of type-2 CRH receptor mRNA in the ventromedial hypothalamus in the rat. J. Neuroendocrinol. 11:1999;307-314.
45. Kastin A.J., et al. Novel peptide-peptide cooperation may transform feeding behavior. Peptides. 23:2002;2189-2196.
46. 2 receptor in rats. Regul. Pept. 113:2003;125-130.
47. Rivier J., et al. Synthetic competitive antagonists of corticotropin-releasing factor: effect on ACTH secretion in the rat. Science. 224:1984;889-891.
48. Zorrilla E.P., et al. Effects of antalarmin, a CRF type 1 receptor antagonist, on anxiety-like behavior and motor activation in the rat. Brain Res. 952:2002;188-199.
49. Rühmann A., et al. Structural requirements for peptidic antagonists of the corticotropin-releasing factor receptor (CRFR): development of CRFR2beta-selective antisauvagine-30. Proc. Natl. Acad. Sci. U. S. A. 95:1998;15264-15269.
50. Gulyas J., et al. Potent, structurally constrained agonists and competitive antagonists of corticotropin-releasing factor. Proc. Natl. Acad. Sci. U. S. A. 92:1995;10575-10579.
51. Rivier J.E., et al. Constrained corticotropin releasing factor antagonists (astressin analogues) with long duration of action in the rat. J. Med. Chem. 42:1999;3175-3182.
52. Nakazato A., et al. Design, synthesis and structure-affinity relationships of 4-methylidenepiperidine and 4-aryl-1,2,3,6-tetrahydropyridine derivatives as corticotropin-releasing factor1 receptor antagonists. Bioorg. Med. Chem. 8:2000;1183-1193.
53. Okuyama S., et al. Receptor binding, behavioral, and electrophysiological profiles of nonpeptide corticotropin-releasing factor subtype 1 receptor antagonists CRA1000 and CRA1001. J. Pharmacol. Exp. Ther. 289:1999;926-935.
54. Miranda A., et al. Conformationally restricted competitive antagonists of human/rat corticotropin-releasing factor. J. Med. Chem. 37:1994;1450-1459.
55. Gilligan P.J., et al. Corticotropin releasing factor (CRF) receptor modulators: progress and opportunities for new therapeutic agents. J. Med. Chem. 43:2000;1641-1660.
56. Heinrichs S.C., et al. Brain penetrance, receptor occupancy and antistress in vivo efficacy of a small molecule corticotropin releasing factor type I receptor selective antagonist. Neuropsychopharmacology. 27:2002;194-202.
57. Mackay K.B., et al. Neuroprotective effects of the CRF1 antagonist R121920 after permanent focal ischemia in the rat. J. Cereb. Blood Flow Metab. 21:2001;1208-1214.
58. 3H]SN003) for corticotropin-releasing factor1 receptors. J. Pharmacol. Exp. Ther. 305:2003;57-69.
59. 1 receptor antagonist. I. Biochemical and pharmacological characterization. J. Pharmacol. Exp. Ther. 301:2002;322-332.
60. Rivier C.L., et al. Role of corticotropin-releasing factor receptors type 1 and 2 in modulating the rat adrenocorticotropin response to stressors. Endocrinology. 144:2003;2396-2403.